RxDoctor Payments Data

Manijeh Javaheri, MD

Internal Medicine · Laguna Hills, CANPI 1639102387

Payments from drug & device makers

$1,405in general payments, 2019–2025

Across 18 payments — averaging $78.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$350
  • Johnson & Johnson$288
  • Novartis$287
  • Amgen$260
  • Biogen$120
  • Pfizer$76
  • plus $24 from 1 others

What the payments were for

  • Food & beverage$1,398100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$350
Johnson & Johnson4$288
Novartis6$287
Amgen2$260
Biogen1$120
Pfizer1$76
Gilead1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,405 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$130,514
Medicare patients
119
Services billed
2,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate22$25,039
ProliaDenosumab15$24,571
EliquisApixaban14$23,867
JardianceEmpagliflozin13$19,423
OzempicSemaglutide17$19,222
Breo ElliptaFluticasone/Vilanterol22$14,606
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$4,056
Albuterol Sulfate HfaAlbuterol Sulfate88$3,039
SynthroidLevothyroxine Sodium19$2,123
Atorvastatin Calcium172$1,392
Rosuvastatin Calcium41$1,355
Tamsulosin Hcl59$1,072
Memantine Hcl33$1,015
Metformin Hcl130$1,007
Levothyroxine Sodium89$910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$260$24,57115 claims
PfizerEliquis$76$23,86714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →